Sign In
Buy PASG
$4.47
-0.0200 (-0.445%)
At Close: Jul 31, 2026
New Strong Sell Stocks for August 12th
12:25pm, Thursday, 12'th Aug 2021
WKHS, SPCE, PASG, LYRA, and GO have been added to the Zacks Rank #5 (Strong Sell) List on August 12, 2021
Passage Bio, Inc. (PASG) Bruce Goldsmith on Q2 2021 Results - Earnings Call Transcript
01:39pm, Sunday, 08'th Aug 2021
Passage Bio, Inc. (PASG) Bruce Goldsmith on Q2 2021 Results - Earnings Call Transcript
Passage Bio Mourns the Sudden Passing of Chairman of the Board Tadataka Yamada, M.D.
09:00pm, Wednesday, 04'th Aug 2021
PHILADELPHIA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system d
Passage Bio to Present at 12th Annual Wedbush PacGrow Healthcare Conference
07:00am, Wednesday, 04'th Aug 2021
PHILADELPHIA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central
Passage Bio Announces Key Executive Appointments
07:00am, Monday, 19'th Jul 2021
Chief Commercial Officer, Chief Financial Officer and Chief Medical Officer to focus on driving company growth and advancing robust pipeline of transformative therapies for patients with CNS disorders
Why Passage Bio Shares Are Trading Higher Today
01:32pm, Thursday, 01'st Jul 2021
Passage Bio (NASDAQ: PASG) shares are trading higher after Raymond James initiated coverage on the stock with an Outperform rating and announced a $29 price target. The firm said the company's gene th
Passage Bio: Price Reduced, But Without Data, Does Not Look Convincing
04:08pm, Sunday, 06'th Jun 2021
Passage Bio has failed considerably since I last covered it. They have also started or are about to start three trials.
Derrell D. Porter, M.D., Elected to Board of Directors of Passage Bio
07:00am, Tuesday, 01'st Jun 2021
PHILADELPHIA, June 01, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central
Passage Bio to Host Virtual R&D Event on May 17
07:00am, Monday, 10'th May 2021
Focus to be on frontotemporal dementia with granulin mutations Focus to be on frontotemporal dementia with granulin mutations
Passage Bio, Inc. (PASG) CEO Bruce Goldsmith on Q1 2021 Results - Earnings Call Transcript
07:08am, Sunday, 09'th May 2021
Passage Bio, Inc. (PASG) CEO Bruce Goldsmith on Q1 2021 Results - Earnings Call Transcript
Passage Bio Receives European Commission Orphan Designation for PBKR03 for Treatment of Krabbe Disease
07:00am, Monday, 05'th Apr 2021
- Krabbe disease, a rare lysosomal storage disorder, has no approved disease-modifying treatment options
Moving Average Crossover Alert: Passage Bio (PASG)
08:20am, Thursday, 01'st Apr 2021
Passage Bio (PASG) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Passage Bio Announces First Patient Dosed in Imagine-1 Study of PBGM01 Gene Therapy for Infantile GM1 Gangliosidosis
07:00am, Thursday, 01'st Apr 2021
– PBGM01 advancement to clinical development represents key milestone for Passage Bio as a clinical-stage company –
Passage Bio to Participate in Upcoming April Investor Conferences
07:00am, Thursday, 25'th Mar 2021
PHILADELPHIA, March 25, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system
Passage Bio Appoints Eliseo O. Salinas, M.D.
07:00am, Monday, 22'nd Mar 2021
PHILADELPHIA, March 22, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system
